Yesterday 08:38 AM
Study finds no statistical link between use of semaglutide and other GLP-1 drugs and risk of degenerative eye disease in adults with type 2 diabetes
https://www.eurekalert.org/news-releases/1136615
INTRO: An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — a type of medication that mimics the GLP-1 hormone — to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.
A new, federally funded retrospective study led by Johns Hopkins Medicine strongly suggests that semaglutide and other GLP-1 RAs did not statistically change the risk of developing neovascular age-related macular degeneration (NVAMD) — a fast-progressing, blinding condition that is caused by uncontrolled, abnormal blood vessel growth in the back of the eye — in adults with type 2 diabetes without a prior history of GLP-1 use.
A peer-reviewed report of the work, funded by the National Institutes of Health, published online in Ophthalmology... (MORE - no ads)
https://www.eurekalert.org/news-releases/1136615
INTRO: An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — a type of medication that mimics the GLP-1 hormone — to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.
A new, federally funded retrospective study led by Johns Hopkins Medicine strongly suggests that semaglutide and other GLP-1 RAs did not statistically change the risk of developing neovascular age-related macular degeneration (NVAMD) — a fast-progressing, blinding condition that is caused by uncontrolled, abnormal blood vessel growth in the back of the eye — in adults with type 2 diabetes without a prior history of GLP-1 use.
A peer-reviewed report of the work, funded by the National Institutes of Health, published online in Ophthalmology... (MORE - no ads)
